Literature DB >> 12773985

Intestinal transformation results in transforming growth factor-beta-dependent alteration in tumor cell-cell matrix interactions.

David H Berger1, Christine A O'Mahony, Hongmiao Sheng, Jinyi Shao, Daniel Albo, Raymond N DuBois, R Daniel Beauchamp.   

Abstract

BACKGROUND: An alteration in the expression of and response to transforming growth factor-beta 1 (TGF-beta 1) appears to be an important event during colorectal carcinogenesis. However, the precise role of TGF-beta 1 in colorectal carcinogenesis is not clear. We have previously described in detail the changes in cell proliferation and differentiation caused by chronic exposure to TGF-beta 1. In this study we sought to better characterize the changes in tumor cell-cell matrix interactions seen during TGF-beta 1-mediated intestinal transformation.
METHODS: Rat intestinal epithelial cells (RIE) and RIE cells transformed by chronic exposure to TGF-beta 1 (RIE-Tr) were treated with TGF-beta 1 and production of components of the plasmin/plasminogen system measured by ELISA and Western blotting. TGF-beta 1 effects on invasion and adhesion were determined in vitro. The role of urokinase on TGF-beta 1-mediated invasion and adhesion were determined using immunoneutralization. The role of COX-2 was determined using a specific COS-2 inhibitor.
RESULTS: TGF-beta 1 had no effect on RIE-1 adhesion to collagen types I and IV, fibronectin, and laminin, or invasion through collagen types I and IV. However, 5 ng/mL TGF-beta 1 significantly increased the invasiveness and decreased the adhesiveness of RIE-Tr. This effect of TGF-beta 1 on RIE-Tr was associated with a significant increase in plasmin activity secondary to increased expression of uPA. TGF-beta 1 had no effect on either uPA receptor or PAI-1 in this system. Antibodies to uPA completely blocked the TGF-beta 1-mediated invasiveness of the RIE-Tr cells and returned their adhesiveness to basement membrane proteins to baseline. Addition of the selective Cox-2 inhibitor SC-58125 resulted in a dose-dependent decrease in TGF-beta 1-mediated invasion and uPA expression.
CONCLUSION: This study provides additional evidence for TGF-beta 1 as a tumor promoter during intestinal carcinogenesis and a possible new mechanism for Cox-2-related colon carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12773985     DOI: 10.1067/msy.2003.125

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  4 in total

1.  Tissue-type plasminogen activator activity in morphologically normal tissues adjacent to gastrointestinal carcinomas is associated with the degree of tumor progression.

Authors:  Gabriel Scicolone; Viviana Sanchez; Liliana Vauthay; Federico Fuentes; Alejandro Scicolone; Lorenzo Scicolone; Melina Rapacioli; Vladimir Flores
Journal:  J Cancer Res Clin Oncol       Date:  2005-12-21       Impact factor: 4.553

2.  Effects of transforming growth factor-beta in the development of inflammatory pseudotumour-like lesions in a murine model.

Authors:  Luciana Doria Guariniello; Mariangela Correa; Miriam Galvonas Jasiulionis; Joel Machado; José Antônio Silva; João Bosco Pesquero; Célia Regina Whitaker Carneiro
Journal:  Int J Exp Pathol       Date:  2006-06       Impact factor: 1.925

3.  Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.

Authors:  Alan P Venook; Donna Niedzwiecki; Margarita Lopatin; Xing Ye; Mark Lee; Paula N Friedman; Wendy Frankel; Kim Clark-Langone; Carl Millward; Steven Shak; Richard M Goldberg; Najjia N Mahmoud; Robert S Warren; Richard L Schilsky; Monica M Bertagnolli
Journal:  J Clin Oncol       Date:  2013-03-25       Impact factor: 44.544

4.  Transforming growth factor beta 1 and metalloproteinase-9 overexpression in colorectal cancer (CC) and adenoma.

Authors:  Piotr Daniel; Malgorzata Wagrowska-Danilewicz; Marian Danilewicz; Olga Stasikowska; Ewa Malecka-Panas
Journal:  Int J Colorectal Dis       Date:  2007-03-30       Impact factor: 2.571

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.